Why Premature Skull Suture Fusion Occurs in XLH: Pediatric Neurosurgery Next Steps

Why Premature Skull Suture Fusion Occurs in XLH: Pediatric Neurosurgery Next Steps

X-linked hypophosphatemia (XLH) is the most common form of inherited rickets. It’s caused by mutations in the PHEX gene that lead to excess fibroblast growth factor 23 (FGF23), phosphate wasting through the kidneys, and low levels of active vitamin D. While XLH is best known for bowed legs and delayed growth, one less obvious risk is premature skull suture fusion—craniosynostosis. Understanding why this happens and how pediatric neurosurgery can help is key to protecting brain development and appearance.

Understanding Craniosynostosis Risk in Hypophosphatemic Rickets

• Craniosynostosis is the early closure of one or more fibrous joints (sutures) between skull bones.
• In XLH, phosphate deficiency and abnormal vitamin D metabolism disrupt normal bone growth and turnover.
• The delicate balance between bone‐forming cells (osteoblasts) and bone‐resorbing cells (osteoclasts) at sutures is upset, promoting premature ossification.
• Although the exact molecular trigger remains under study, data suggest that altered osteocyte signaling (due to high FGF23) accelerates suture closure.

Why Phosphate Matters for Skull Growth

The skull grows in response to brain expansion. Patent sutures allow the skull to expand evenly and relieve pressure on the developing brain. In XLH:

1. Hypophosphatemia (low blood phosphate) leads to osteoid accumulation and poor mineralization of bone, forcing compensatory changes in suture biology.
2. Excess FGF23 reduces active vitamin D, further weakening bone quality.
3. To maintain structural integrity, sutures may ossify earlier than normal, limiting growth potential.

Because skull shape and brain growth are tightly linked, closed sutures can raise intracranial pressure, threaten vision, and affect neurodevelopment if left untreated.

Who Is at Highest Risk?

Not every child with XLH will develop craniosynostosis, but certain factors increase the odds:

• Severity of phosphate loss (more pronounced hypophosphatemia)
• Very early onset of rickets symptoms (<1 year old)
• Family history of suture abnormalities in XLH
• Delayed or suboptimal medical therapy for XLH

Early identification of risk factors allows prompt monitoring and intervention.

Recognizing Signs and Symptoms

Because skull fusion patterns vary, presentation can range from subtle to pronounced. Key signs include:

• Abnormal head shape
– Plagiocephaly (flattened side of the skull)
– Brachycephaly (wide, short head)
– Scaphocephaly (long, narrow head)
• Palpable palpable ridges along fused sutures
• Slow or halted increase in head circumference
• Irritability, poor feeding, or vomiting (signs of raised intracranial pressure)
• Developmental delays or changes in sleep patterns

Any of these findings in a child with XLH should trigger prompt evaluation by a pediatric neurosurgeon.

Diagnostic Work-Up

A stepwise approach helps confirm craniosynostosis and plan treatment:

1. Clinical exam
   – Head measurement, suture palpation, fontanelle assessment
2. Skull imaging
   – Low-dose CT with 3D reconstruction is the gold standard to identify which sutures are fused
3. Ophthalmology evaluation
   – Check for papilledema or vision changes from raised intracranial pressure
4. Baseline developmental assessment
   – Neurodevelopmental screening to guide therapy timing

Once fusion is confirmed, a multidisciplinary team—including endocrinology, neurosurgery, and craniofacial specialists—will outline next steps.

Pediatric Neurosurgery Next Steps

Timely surgical intervention can normalize skull shape, relieve pressure, and support healthy brain development. The choice of procedure depends on the child’s age, which sutures are closed, and overall health:

• Endoscopic suturectomy
– Best for infants under 6 months
– Minimally invasive removal of fused suture segment
– Often followed by helmet therapy to guide skull growth
• Open cranial vault remodeling
– For children older than 6–9 months or with complex/multiple suture fusions
– Involves reshaping and repositioning bone segments
• Posterior vault expansion
– Particularly for multi‐suture or syndromic cases
– Increases intracranial volume

Timing is critical: early surgery (ideally before 1 year of age) tends to yield the best cosmetic and neurodevelopmental outcomes. However, the team will balance surgical risk, anesthesia considerations, and the child’s overall bone health.

Optimizing Medical Management in Parallel

Surgery addresses skull shape and pressure but doesn’t correct the underlying mineral imbalance. Close collaboration with a pediatric endocrinologist is essential:

• Oral phosphate supplements and active vitamin D analogs
– Help normalize bone mineralization
– May slow progression of suture fusion
• Burosumab (anti-FGF23 antibody)
– Targets the root cause of phosphate wasting in XLH
– Emerging data suggest it may reduce skeletal complications over time
• Regular monitoring of serum phosphate, calcium, and alkaline phosphatase
– Dosing adjustments to avoid side effects (e.g., hypercalciuria)

Combined medical and surgical care improves long-term head shape, reduces reoperation rates, and supports overall growth.

Long-Term Follow-Up

Children treated for XLH and craniosynostosis need ongoing surveillance:

• Periodic head circumference and developmental assessments
• Repeat imaging only if new symptoms arise
• Monitoring for dental issues, bone deformities, and hearing changes
• Transition planning to adult metabolic bone and neurosurgery teams

With coordinated care, most children achieve normal neurodevelopment and stable skull shape.

Key Takeaways

• Craniosynostosis in XLH stems from phosphate deficiency and abnormal FGF23 activity disrupting skull suture biology.
• Risk factors include severe hypophosphatemia, early rickets onset, and family history.
• Signs such as abnormal head shape or rising intracranial pressure warrant immediate imaging and specialist referral.
• Surgical options (endoscopic suturectomy or cranial vault remodeling) are most effective before 12 months of age.
• Ongoing medical therapy for XLH—phosphate, active vitamin D, or burosumab—supports bone health and may reduce suture-fusion risk.

If your child with XLH shows any warning signs, you might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to guide your next steps. As always, speak to a doctor about any life-threatening or serious concerns. Early assessment and a coordinated specialist team give every child the best chance for healthy development.